Budget impact of botulinum toxin treatment for spasticity after stroke — a German perspective (original) (raw)
Cost-Effectiveness of Treating Upper Limb Spasticity Due to Stroke with Botulinum Toxin Type A: Results from the Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial
Lisa Anderson-Shaw
Toxins, 2012
View PDFchevron_right
Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study
Nicholas Moore
Journal of Neurology, 2011
View PDFchevron_right
Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom
Edit Remak
ClinicoEconomics and Outcomes Research, 2015
View PDFchevron_right
Cost-effectiveness: a new criterion for selecting therapy
Bengt Jonsson
Journal of Internal Medicine, 1995
View PDFchevron_right
Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity
Anthony Ward
Journal of Rehabilitation Medicine, 2005
View PDFchevron_right
AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: An cost-utility analysis
Carlo Lazzaro
Journal of Rehabilitation Medicine, 2019
View PDFchevron_right
Economics of botulinum toxin therapy: influence of the abobotulinumtoxinA package size on the costs of botulinum toxin therapy
Fereshte Adib Saberi
Basal Ganglia, 2015
View PDFchevron_right
A modified balance-sheet procedure for decision making in therapy: Cost^cost comparisons
Sheri Oz
Professional Psychology-research and Practice, 1995
View PDFchevron_right
Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy in the Management of Post-Stroke Spasticity in Romania
Adina Turcu-Stiolica
Frontiers in Pharmacology, 2020
View PDFchevron_right
A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity
Emanuel Engmann
Toxins
View PDFchevron_right
Protocol for the economic evaluation of the InTENSE program for rehabilitation of chronic upper limb spasticity
Louise Ada
BMC Health Services Research, 2020
View PDFchevron_right
Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study
Samuel Pascual
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2016
View PDFchevron_right
Economics of dry needling and botulinum toxin type A for treatment of post-stroke spasticity: a review
Eva Gómez-Trullén
Exploration of Neuroprotective Therapy
View PDFchevron_right
Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada
Savreet Bains
Journal of Medical Economics
View PDFchevron_right
Quality of life and costs of spasticity treatment in German stroke patients
Dirk Dressler
Health Economics Review, 2016
View PDFchevron_right
BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A
Frederike M J Van Wijck
Health technology assessment (Winchester, England), 2010
View PDFchevron_right
Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population
Rashid Kazerooni
Journal of Managed Care & Specialty Pharmacy, 2021
View PDFchevron_right
Evidence from cost-effectiveness research
Katia Noyes
NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2004
View PDFchevron_right
Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries
Hannah Kurth
Medical Devices: Evidence and Research, 2012
View PDFchevron_right
Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System
giulio Del Popolo
World Journal of Urology, 2014
View PDFchevron_right
Whither trial-based economic evaluation for health care decision making?
Mike Drummond, Karl Claxton
Health Economics, 2006
View PDFchevron_right
Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia
Rashid Kazerooni
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015
View PDFchevron_right
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
Dawn Lee
Value in Health, 2016
View PDFchevron_right
Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK …
Clare Fowler
European urology, 2006
View PDFchevron_right
German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus
S. Felder, Timm Volmer, H. Selbmann
Value in Health, 2008
View PDFchevron_right
Cost issues in sequential therapy
Jonathan Cooke
Journal of Infection, 1998
View PDFchevron_right
Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial
Sadie Wickwar
View PDFchevron_right
Cost-Benefit Analysis, Monetary Value, and Medical Decision
Robert Audi
Philosophy and Medicine, 1986
View PDFchevron_right
Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom
Madhusubramanian Muthukumar
ClinicoEconomics and Outcomes Research
View PDFchevron_right
Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists
Christopher McCabe
View PDFchevron_right
A one-year prospective costing study of botulinum toxin type A treatment of chronic tension headache
Fabio Palazzo
The Journal of Headache and Pain, 2004
View PDFchevron_right
Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis
Myriam G M Hunink
Medical Decision Making, 2007
View PDFchevron_right
Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A
Gary A Ford
2008
View PDFchevron_right